Edition:
United States

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

6.62USD
3:59pm EST
Change (% chg)

$0.01 (+0.15%)
Prev Close
$6.61
Open
$6.58
Day's High
$6.81
Day's Low
$6.42
Volume
39,461
Avg. Vol
90,308
52-wk High
$22.02
52-wk Low
$6.15

Latest Key Developments (Source: Significant Developments)

Kala Pharmaceuticals Q3 Loss Per Share $0.63
Thursday, 8 Nov 2018 07:30am EST 

Nov 8 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.63.Q3 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, KALA HAD CASH OF $74.9 MILLION COMPARED TO $114.6 MILLION AS OF DECEMBER 31, 2017.KALA PHARMACEUTICALS - EXISTING CASH AS OF SEPT 30, 2018 COMBINED WITH PROCEEDS FROM OCTOBER 2018 FINANCINGS WILL EXTEND THROUGH AT LEAST EARLY 2020.STRIDE 3 TRIAL FOR DYE EYE DISEASE IS ENROLLING, AND WE ARE ON TRACK TO REPORT TOPLINE DATA IN Q4 2019.  Full Article

Kala Pharmaceuticals Announces Financing From Athyrium Capital Management Totaling $110 Million
Tuesday, 2 Oct 2018 04:18pm EDT 

Oct 2 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES FINANCING FROM ATHYRIUM CAPITAL MANAGEMENT TOTALING $110 MILLION.KALA PHARMACEUTICALS INC - EXPECT THE FINANCING TO SUPPORT KALA'S EFFORTS TO ACHIEVE SIGNIFICANT MILESTONES.KALA PHARMACEUTICALS INC - EXPECTS NDA FILING FOR KPI-121 0.25% FOR DRY EYE DISEASE BY END OF 2018, LAUNCH OF INVELTYS IN EARLY 2019.KALA PHARMACEUTICALS INC - EXPECTS TOPLINE RESULTS FOR STRIDE-3 TRIAL OF KPI-121 0.25% EXPECTED IN Q4 2019.KALA PHARMACEUTICALS INC - CLOSING OF KALA'S $110 MILLION CREDIT FACILITY WITH FUNDS MANAGED BY ATHYRIUM CAPITAL MANAGEMENT.  Full Article

Kala Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 2 Oct 2018 04:18pm EDT 

Oct 2 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.KALA PHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 7.5 MILLION SHARES OF ITS COMMON STOCK.  Full Article

Kala Pharmaceuticals Inveltys Wins FDA Approval
Thursday, 23 Aug 2018 02:49pm EDT 

Aug 23 (Reuters) - :KALA PHARMACEUTICALS INVELTYS WINS FDA APPROVAL.  Full Article

Kala Pharmaceuticals Announces FDA Approval Of Inveltys
Thursday, 23 Aug 2018 01:46pm EDT 

Aug 23 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF INVELTYS™ FOR THE TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY.SAYS EXPECTS TO REPORT TOP-LINE RESULTS FOR STRIDE 3 IN Q4 OF 2019.SAYS EXPECT TO LAUNCH INVELTYS IN BEGINNING OF 2019.SAYS PLANS TO SUBMIT A NEW DRUG APPLICATION FOR KPI-121 0.25% DURING H2 OF 2018.  Full Article

Kala Pharmaceuticals Inc Files For Mixed Shelf Of Upto $250 Million
Thursday, 9 Aug 2018 05:43pm EDT 

Aug 9 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING.KALA PHARMACEUTICALS INC SAYS IN ADDITION, ENTERED INTO SALES AGREEMENT WITH JEFFERIES LLC FOR SALE OF SHARES OF CO'S COMMON STOCK OF UP TO $50.0 MILLION.  Full Article

Kala Pharmaceuticals Q2 Loss Per Share $0.60
Thursday, 9 Aug 2018 07:00am EDT 

Aug 9 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.60.Q2 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.  Full Article

Kala Pharmaceuticals Reports Q1 Loss Per Share Of $0.46
Thursday, 10 May 2018 07:00am EDT 

May 10 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.46.Q1 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, HAD CASH OF $100.5 MILLION COMPARED TO $114.6 MILLION AS OF DECEMBER 31, 2017.ANTICIPATES THAT ITS EXISTING CASH ON HAND WILL ENABLE IT TO FUND OPERATIONS THROUGH AT LEAST NEXT TWELVE MONTHS.  Full Article

Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46
Monday, 26 Mar 2018 07:00am EDT 

March 26 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.46.Q4 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.ENDED 2017 WITH $114.6 MILLION IN CASH.PDUFA TARGET ACTION DATE FOR INVELTYS IS AUGUST 24, 2018.  Full Article

Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals
Friday, 12 Jan 2018 05:14pm EST 

Jan 12 (Reuters) - Kala Pharmaceuticals Inc ::ORBIMED ADVISORS LLC REPORTS ABOUT 11 PERCENT PASSIVE STAKE IN KALA PHARMACEUTICALS INC AS OF JAN 10.  Full Article

Photo

FDA approves Kala Pharma's eye pain drug

The U.S. Food and Drug Administration on Thursday approved Kala Pharmaceuticals Inc's treatment for reducing inflammation and pain following an eye surgery.